|
|
| (+)-JJ-74-138 / J&J (0 Trials) |
|
| (+)-α-dihydrotetrabenazine (ADE 513) / Adeptio Pharma (0 Trials) |
|
| (+)-β-dihydrotetrabenazine / Adeptio Pharma (0 Trials) |
|
| (R)-ketamine nasal spray (HS-10345) / Jiangsu Hansoh Pharma (0 Trials) |
|
| 1% capsaicin topical liquid (CGS-200-1) / Vizuri Health Sci (0 Trials) |
|
| 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead (0 Trials) |
|
| 10-1074-LS-J / IAVI, Rockefeller University (0 Trials) |
|
| 10058-F4 / Children's Hospital of Pittsburgh of UPMC, UPMC Hillman Cancer Center (0 Trials) |
|
| 10E8.4/iMab / Bill & Melinda Gates Foundation, IAVI, TaiMed Biologics (0 Trials) |
|
| 11-valent recombinant HPV vaccine / Sinopharm (0 Trials) |
|
| 111In-DOTA-h11B6 / J&J (0 Trials) |
|
| 11ßHSD / Ipsen (0 Trials) |
|
| 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino (0 Trials) |
|
| 131I-iodofalan (TLX101) / Telix (0 Trials) |
|
| 14028 injection (dulaglutide biosimilar) / Sunshine Lake Pharma (0 Trials) |
|
| 14aj / Nankai University School of medicine (0 Trials) |
|
| 15N2-tofacitinib (TD-3504) / Zymeworks (0 Trials) |
|
| 161Tb-DOTA-LM3 / Paul Scherrer Institute, University Hospital Basel (0 Trials) |
|
| 162 / Yangshengtang (0 Trials) |
|
| 1650-G allogeneic cellular vaccine / University of Kentucky (0 Trials) |
|
| 17 beta hydroxysteroid dehydrogenase inhibitor / ElexoPharm (0 Trials) |
|
| 177Lu HTK03170 / BC Cancer Agency (0 Trials) |
|
| 177Lu-BiOncoFAP / Philogen (0 Trials) |
|
| 177Lu-capromab pendetide (CYT 500) / Jazz (0 Trials) |
|
| 177Lu-DOTA-girentuximab (TLX250) / Telix (0 Trials) |
|
| 177Lu-DTPA-omburtamab / SERB Pharmaceuticals (0 Trials) |
|
| 177Lu-DTPA-SC16 / Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine (0 Trials) |
|
| 177Lu-EBTATE / Molecular Targeting Tech (0 Trials) |
|
| 177Lu-LNC1003 / Lannacheng Biotechnology (0 Trials) |
|
| 177Lu-LNC1004 / Lannacheng Biotechnology (0 Trials) |
|
| 177Lu-LNC1004 / Dongcheng Pharma (0 Trials) |
|
| 177Lu-LNC1010 / Lannacheng Biotechnology (0 Trials) |
|
| 177Lu-OncoFAP-23 / Philogen (0 Trials) |
|
| 177Lu-P17-087 / Five Eleven Pharma (0 Trials) |
|
| 177Lu-P17-088 / Five Eleven Pharma (0 Trials) |
|
| 177Lu-PSMA-R2 / Novartis (0 Trials) |
|
| 177Lu-rosopatamab tetraxetan (TLX591) / Telix (3 Trials) |
|
| 177Lu-TE-1132 / T-E Pharma (0 Trials) |
|
| 177Lu-zoledronate (ITM-41) / ITM Isotope Technologies Munich (0 Trials) |
|
| 177LuFF-10158 / Novartis, Fujifilm Holdings (0 Trials) |
|
| 17D Yellow fever vaccine / Institut Pasteur (0 Trials) |
|
| 18F-BMS-986229 / BMS (0 Trials) |
|
| 19273-4SCAR / University of South Florida, Peking Union Medical College (1 Trials) |
|
| 19GJ / Pfizer (0 Trials) |
|
| 19H6-Hu / 3SBio (0 Trials) |
|
| 1B7/31F anti-GD2 antibody therapeutic / BioNTech (0 Trials) |
|
| 1c-SApNP VLP vaccine / Ufovax (0 Trials) |
|
| 1ST-101 / 1ST Bio (0 Trials) |
|
| 1ST-105 / D&D Pharmatech, 1ST Bio (0 Trials) |
|
| 1ST-201 / 1ST Bio (0 Trials) |
|
| 1ST-202 / 1ST Bio (0 Trials) |
|
| 1ST-203 / 1ST Bio (0 Trials) |
|
| 1ST-204 / 1ST Bio (0 Trials) |
|
| 1ST-205 / 1ST Bio, Aria Pharma (0 Trials) |
|
| 1ST-206 / 1ST Bio (0 Trials) |
|
| 1ST-301 / 1ST Bio (0 Trials) |
|
| 1st Shared TruTCR based cell therapy / Roche (0 Trials) |
|
| 2,3- benzodiazepine analog / Climb Bio (0 Trials) |
|
| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci (0 Trials) |
|
| 2-fluorofucose (SGN-2FF) / Pfizer (0 Trials) |
|
| 2-methoxyestradiol analogues (CP 2117) / Cryptopharma (0 Trials) |
|
| 2019-nCoV DNA vaccine / Takis (0 Trials) |
|
| 2019-nCoV therapeutic antibody / University of South China (0 Trials) |
|
| 20A77 / Chiome Biosci (0 Trials) |
|
| 211At-OKT10-B10 / Fred Hutchinson Cancer Center (0 Trials) |
|
| 212 Pb-ADVC001 / AdvanCell Isotopes (0 Trials) |
|
| 212Pb-DOTAM-GRPR1 / Orano (0 Trials) |
|
| 2141-V11 / Memorial Sloan-Kettering Cancer Center, Rockefeller University (0 Trials) |
|
| 21BW / Pfizer (0 Trials) |
|
| 225Ac-daratumumab / Actinium (0 Trials) |
|
| 225Ac-DOTA-daratumumab / City of Hope (0 Trials) |
|
| 225Ac-FAP-2286 / Clovis, 3B Pharma (0 Trials) |
|
| 225Ac-FL-020 / Full-Life Technologies Limited (0 Trials) |
|
| 225Ac-PSMA-62 / Eli Lilly (0 Trials) |
|
| 225Ac-rhPSMA-10.1 / Blue Earth Therapeutics (0 Trials) |
|
| 225Ac-vipivotide tetraxetan (AAA817) / Novartis (0 Trials) |
|
| 23-valent PPV / Sinovac (0 Trials) |
|
| 23A11 / Oxurion (0 Trials) |
|
| 23C6 / TellBio (0 Trials) |
|
| 23ME-00610 / 23andMe (0 Trials) |
|
| 27 / Hanmi (0 Trials) |
|
| 27T51 / Regeneron (0 Trials) |
|
| 2aG4 / Avid Bioservices (0 Trials) |
|
| 2C3 / Avid Bioservices, Affitech (0 Trials) |
|
| 2nd Generation HDAC Inhibitor / San Rocco Therap (0 Trials) |
|
| 2nd generation modalities / Axonis (0 Trials) |
|
| 2nd Shared TruTCR based cell therapy / Adaptive Biotech, Roche (0 Trials) |
|
| 2R,6R-hydroxynorketamine hydrochloride ((2R,6R)-HNK) / National Institute of Mental Health (0 Trials) |
|
| 2X-131 / Allarity Therap (0 Trials) |
|
| 2‐hydroxyoleic acid (NFX88) / Neurofix (0 Trials) |
|
| 3-day fentanyl transdermal patch / Generic mfg. (4 Trials) |
|
| 33C3 / AstraZeneca (0 Trials) |
|
| 3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead (4 Trials) |
|
| 3BNC117-LS-J / Rockefeller University, IAVI (0 Trials) |
|
| 3D011 / 3DMed (0 Trials) |
|
| 3D1-MMAE / XYone Therap (0 Trials) |
|
| 3Fluart (influenza vaccine) / Fluart Innovative Vaccines (0 Trials) |
|
| 3K3A-APC / ZZ Biotech (0 Trials) |
|
| 3PO / Advanced Cancer Therapeutics (0 Trials) |
|
| 3T3-mIL10 / Eli Lilly (0 Trials) |
|
| 3VM1001 / CDA Research Group (1 Trials) |
|
| 4'-Thio-2'-Deoxycytidine (TdCyd) / National Cancer Institute (1 Trials) |
|
| 4-1BBxTAA bispecific antibody / Zymeworks (0 Trials) |
|
| 4-Antigen EBV Vaccine / Citranvi Biosci (0 Trials) |
|
| 4-hydroxytestosterone transdermal (CR 1477) / Curadis (1 Trials) |
|
| 402 TCR / T-Cure Biosci (0 Trials) |
|
| 4D-110 / 4D Molecular Therap, Roche (0 Trials) |
|
| 4D-125 / 4D Molecular Therap (0 Trials) |
|
| 4D-175 / 4D Molecular Therap (0 Trials) |
|
| 4D-310 / 4D Molecular Therap (0 Trials) |
|
| 4D-710 / 4D Molecular Therap (0 Trials) |
|
| 4D-725 / 4D Molecular Therap (0 Trials) |
|
| 4P FSH / Nutriband (0 Trials) |
|
| 4SC 203 / 4SC (0 Trials) |
|
| 4SC 301 / 4SC (0 Trials) |
|
| 4SC-208 / 4SC (0 Trials) |
|
| 4SCAR-276 / SZGIMI (0 Trials) |
|
| 4SCAR-CD22/CD123/CD38/CD10/CD20 infusion / SZGIMI (0 Trials) |
|
| 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR / SZGIMI (0 Trials) |
|
| 4SCAR-CD44v6 T Cell Therapy / SZGIMI (0 Trials) |
|
| 4SCAR-PSMA T cells / SZGIMI (0 Trials) |
|
| 4SCAR30273 / University of South Florida, Peking Union Medical College (1 Trials) |
|
| 4SCAR38 / SZGIMI (0 Trials) |
|
| 4WF / Esperion Therap (0 Trials) |
|
| 5% capsaicin topical liquid (CGS-200-5) / Astellas (0 Trials) |
|
| 5-ALA with CV01 / Alpheus Medical (0 Trials) |
|
| 5-aminolevulinic acid (5-ALA iPDT) / SBI Holdings (0 Trials) |
|
| 5-aminolevulinic acid (5-ALA) / Fox Chase Cancer Center (0 Trials) |
|
| 5-fluorouracil / Generic mfg. (1510 Trials) |
|
| 5-HT1A partial agonist / Suven Life Sci (0 Trials) |
|
| 5-Hydroxytriptolide / Shanghai Pharma (0 Trials) |
|
| 5-lipoxygenase inhibitor / Qurient (0 Trials) |
|
| 5-methoxy-dimethyltryptamine injection (GH002) / GH Research (0 Trials) |
|
| 5-methoxy-dimethyltryptamine liquid intranasal (BPL-002) / AtaiBeckley (0 Trials) |
|
| 5-methoxy-N,N-dimethyltryptamine (BMND08) / Biomind (0 Trials) |
|
| 509PXN0001 / Priaxon (0 Trials) |
|
| 514G3 / XBiotech (0 Trials) |
|
| 5A apoA-I mimetic peptide / Longevity Biotech (0 Trials) |
|
| 5HT2c agonist program / Athersys (0 Trials) |
|
| 5P12-RANTES / Orion Biotech (0 Trials) |
|
| 6-antigen hCMV vaccine / Citranvi Biosci (0 Trials) |
|
| 601A / 3SBio (0 Trials) |
|
| 609A / 3SBio (0 Trials) |
|
| 611 / 3SBio (0 Trials) |
|
| 64B / OncoSpherix (0 Trials) |
|
| 6MW3511 / Mabwell (Shanghai) Biosci (0 Trials) |
|
| 6RK73 / Mission Therap (0 Trials) |
|
| 7-day rasagiline patch (TPU-002) / Teikoku (0 Trials) |
|
| 7-Day rivastigmine (patch) / Teikoku (0 Trials) |
|
| 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute (0 Trials) |
|
| 7-oxoprasterone (HL-9001) / Humanetics (0 Trials) |
|
| 7C6 mAb / Dana-Farber Cancer Institute (0 Trials) |
|
| 8-MOP (methoxsalen hard gelatin capsules) / Bausch Health (1 Trials) |
|
| 800 TCR / T-Cure Biosci (0 Trials) |
|
| 806 TCR / T-Cure Biosci (0 Trials) |
|
| 8B6 / OGD2 Pharma (0 Trials) |
|
| 8MW2311 / Mabwell (Shanghai) Biosci (0 Trials) |
|
| 8R-70CAR T / University of Florida (0 Trials) |
|
| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech (0 Trials) |
|
| 90Y-besilesomab (TLX66) / Telix (0 Trials) |
|
| 90Y-besilesomab (TLX66) / Telix (0 Trials) |
|
| 90Y-NM600 / Archeus Technologies (0 Trials) |
|
| 90Y-PPMX-T002 / Perseus Proteomics (1 Trials) |
|
| 9F7-F11 / GamaMabs, Montpellier Cancer Research Institute (0 Trials) |
|
| 9MW0813 (aflibercept biosimilar) / Mabwell (Shanghai) Biosci (0 Trials) |
|
| 9MW1111 / Mabwell (Shanghai) Biosci (0 Trials) |
|
| 9MW1411 / Mabwell (Shanghai) Biosci (0 Trials) |
|
| 9MW1911 / Mabwell (Shanghai) Biosci (0 Trials) |
|
| [177Lu]FAPI-46 / Novartis (0 Trials) |
|
| [177Lu]ludotadipep (177 Lu-FC705) / FutureChem (0 Trials) |
|
| [225 Ac]FAPI-46 / Novartis (0 Trials) |
|
| A 443654 / AbbVie (0 Trials) |
|
| A 60 / MabVax (0 Trials) |
|
| A 866111 / AbbVie (0 Trials) |
|
| A 947864 / AbbVie (0 Trials) |
|
| A(H5N1) sa-mRNA influenza vaccine / CSL Behring (0 Trials) |
|
| A-1331852 / AbbVie (0 Trials) |
|
| A-1592668 / AbbVie (0 Trials) |
|
| A-319 / ITabMed (0 Trials) |
|
| A-329 / ITabMed (0 Trials) |
|
| A-337 / ITabMed (0 Trials) |
|
| A-620223 / AbbVie (0 Trials) |
|
| A-705253 / AbbVie (0 Trials) |
|
| A-967079 / AbbVie (1 Trials) |
|
| A000830 / Arcus Biosci (0 Trials) |
|
| A001421 / Arcus Biosci (0 Trials) |
|
| A006 / MeiraGTx (0 Trials) |
|
| A168 (ramucirumab biosimilar) / Sichuan Kelun Pharma (0 Trials) |
|
| A186 / Sichuan Kelun Pharma (0 Trials) |
|
| A204 / Sichuan Kelun Pharma (0 Trials) |
|
| A223 / Sichuan Kelun Pharma (0 Trials) |
|
| A244/B.63521 with ALFQ adjuvant / U.S. Army Medical Research and Development Command (0 Trials) |
|
| A277 / Sichuan Kelun Pharma (0 Trials) |
|
| A289 / Sichuan Kelun Pharma (0 Trials) |
|
| A295 / Sichuan Kelun Pharma (0 Trials) |
|
| A296 / Sichuan Kelun Pharma (0 Trials) |
|
| A2A-04 / A2A Pharma, OncoCube Therap (0 Trials) |
|
| A2A_C01 / A2A Pharma, Daewoong Pharma (0 Trials) |
|
| A2AR inhibitor / General Intermediates Canada (0 Trials) |
|
| A2B530 / A2 Biotherap (0 Trials) |
|
|